FDA warns about the risk of HBV reactivation in patients treated with DAA for HCV-infection
October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with …